IMIDAZOLINE RECEPTOR AGONISTS: DO WE KNOW EVERYTHING ABOUT THEIR CAPABILITIES?

IMIDAZOLINE RECEPTOR AGONISTS: DO WE KNOW EVERYTHING ABOUT THEIR CAPABILITIES?

Show other versions (1)

The role of selective I1 imidazoline receptor agonists and moxonidine in particular , in modern antihypertensive therapy is discussed. Moxonidine advantages, namely positive effects on insulin resistance, endothelial dysfunction, lipid profile, and plasma fibrinolytic activity are considered.

Bibliographic Details
Main Authors:	D. V. Nebieridze, T. V. Kamyshova
Format:	Article
Language:	English
Published:	Столичная издательская компания 2015-12-01
Series:	Рациональная фармакотерапия в кардиологии
Subjects:	arterial hypertension imidazoline receptor agonists moxonidine
Online Access:	https://www.rpcardio.online/jour/article/view/564

Similar Items

IMIDAZOLINE RECEPTOR AGONISTS: DO WE KNOW EVERYTHING ABOUT THEIR CAPABILITIES?
by: D. V. Nebieridze, et al.
Published: (2015-12-01)

Place of imidazoline receptor agonists in the treatment of arterial hypertension
by: D. V. Nebieridze, et al.
Published: (2023-12-01)

COMBINATION OF ACE INHIBITOR WITH AGONIST OF I1 -IMIDAZOLINE RECEPTORS: NEW OPPORTUNITIES FOR ANTIHYPERTENSIVE THERAPY
by: S. V. Nedogoda
Published: (2016-12-01)

Imidazoline receptors in the heart: a novel target and a novel mechanism of action that involves atrial natriuretic peptides
by: S. Mukaddam-Daher, et al.
Published: (2004-08-01)

Imidazoline receptors ligands
by: Agbaba Danica, et al.
Published: (2012-01-01)

Metabolic and antihypertensive effects of moxonidine and moxonidine plus irbesartan in patients withtype 2 diabetes mellitus and mild hypertension:a sequential, randomized, double-blind clinical trial
by: - Giuseppe Derosa, et al.
Published: (2009-03-01)

Treatment of hypertension in overweight patients
by: V G Kukes, et al.
Published: (2015-09-01)

Conceptual Model for Using Imidazoline Derivative Solutions in Pulpal Management
by: Robert S. Jones
Published: (2021-03-01)

LIGAND OF PERIPHERAL IMIDAZOLINE RECEPTORS BASED ON AMIDES OF HETEROCYCLIC ACIDS C7070: EFFECT ON ISHEMIZED TISSUES
by: Anton Dovgan
Published: (2017-12-01)

Molecular Modeling, Synthesis, and Antihyperglycemic Activity of the New Benzimidazole Derivatives – Imidazoline Receptor Agonists
by: Martynov A, et al.
Published: (2024-04-01)

Effects of the number of imidazoline ring and the length of alkyl group chain of imidazoline derivatives on corrosion inhibition of carbon steel in HCl solution: Molecular simulation and experimental validation
by: Chenfeng Zhang, et al.
Published: (2022-12-01)

Methoxyphenyl Imidazolines as Potential Activators of p53
by: Daniil R. Bazanov, et al.
Published: (2022-11-01)

Clinical and Pharmacological Approaches to the Prescription of Centrally Acting Antihypertensive Drugs for Uncontrolled Arterial Hypertension
by: A. V. Strygin, et al.
Published: (2020-11-01)

Study on the Synthesis and Corrosion Inhibition Performance of Mannich-Modified Imidazoline
by: Xiangjun Kong, et al.
Published: (2016-07-01)

Neuroprotective Effects of Dexmedetomidine against Thapsigargin-induced ER-stress via Activity of α<sub>2</sub>-adrenoceptors and Imidazoline Receptors
by: Manami Inagaki, et al.
Published: (2016-07-01)

Patients with arterial hypertension associated with metabolic disorders: characteristics and therapeutic approach
by: Yu V Zhernakova, et al.
Published: (2015-03-01)

Palladium-Catalyzed Multicomponent Synthesis of 2-Imidazolines from Imines and Acid Chlorides
by: Boran Xu, et al.
Published: (2012-11-01)

The imidazoline receptors and the central regulation of the arterial blood pressure: a minireview
by: Eduardo Tibiriça, et al.
Published: (1993-06-01)

Hypertension treatment features in perimenopausal women
by: Yu V Zhernakova, et al.
Published: (2014-03-01)

A Prospective Real World Experience of Moxonidine Use in Indian Hypertensive Patients–Prescription beyond Current Guidelines
by: Suresh V Sagarad, et al.
Published: (2013-10-01)

Studies Of Possible Use Of Oleic Imidazoline As Modifying Agent For Hard Bitumen
by: Zieliński K., et al.
Published: (2015-03-01)

Approaches to the treatment of uncontrolled hypertension. Place of the Physiotens®
by: S. N. Tereshchenko, et al.
Published: (2021-07-01)

The role of the vegetative part of sympathetic nervous system in development of cardiovascular complications in patients with arterial hypertension: pharmacological aspects
by: S R Gilyarevsky
Published: (2014-09-01)

Synthesis and properties of imidazoline corrosion inhibitor for hydraulic support concentrate
by: Dong SHEN, et al.
Published: (2023-08-01)

Effects of Moxonidine Administration on Serum Neuropeptide Y Levels in Hypertensive Individuals: A Prospective Observational Study
by: Eleni Karlafti, et al.
Published: (2022-01-01)

Evaluation of the antihypertensive efficacy and safety of moxonidine in the treatment of uncomplicated hypertensive crisis
by: S N Tereshchenko, et al.
Published: (2013-03-01)

Synthesis and carbonic anhydrase activating properties of a series of 2-amino-imidazolines structurally related to clonidine1
by: Niccolò Chiaramonte, et al.
Published: (2020-01-01)

Anion Exchange Membranes Based on Imidazoline Quaternized Polystyrene Copolymers for Fuel Cell Applications
by: Li-Cheng Jheng, et al.
Published: (2021-11-01)

Effects of Dexmedetomidine on the Localization of α2A-Adrenergic and Imidazoline Receptors in Mouse Testis
by: Hayato Nomura, et al.
Published: (2022-10-01)

Imidazoline-I2 PET Tracers in Neuroimaging
by: Christine A. Parker, et al.
Published: (2023-06-01)

Thymoquinone activates imidazoline receptor to enhance glucagon-like peptide-1 secretion in diabetic rats
by: Shu Ping Lee, et al.
Published: (2019-07-01)

Allantoin ameliorates chemically-induced pancreatic β-cell damage through activation of the imidazoline I3 receptors
by: Marie Amitani, et al.
Published: (2015-08-01)

Pharmacoeconomic analysis of physiotens in patientswith arterial hypertension, overweight and type 2 diabetes mellitusin framework of Russian Public Health System
Published: (2009-09-01)

The role of hypersympathycotony in development of arterial hypertensionin patients with metabolic syndrome: potential of pathogenetically sound therapy
by: A S Ametov, et al.
Published: (2004-12-01)

Modulation of NMDA receptor activity by CR4056, an imidazoline-2 receptor ligand with analgesic properties
by: Giulia Puja, et al.
Published: (2022-09-01)

Place of imidazoline receptor agonists in the treatment of hypertension
by: D. V. Nebieridze, et al.
Published: (2022-01-01)

Evaluation of Decongestive Effect of Topical Imidazoline Derivatives and Oral Pseudoephedrine with Acoustic Rhinometry in Healthy Subjects
by: Ali Özdek, et al.
Published: (2003-03-01)

MOLECULAR DOCKING, 3D-QSAR AND DE NOVO DESIGN OF BENZIMIDAZOLES AND IMIDAZOLINES (S)-ISOTHIAZOLIDINONES DERIVATIVES AS PTP 1B INHIBITORS
by: Judith C. GRANADOS R., et al.
Published: (2010-11-01)

Corrosion behaviors of Q235 carbon steel under imidazoline derivatives as corrosion inhibitors: Experimental and computational investigations
by: Liping Xiong, et al.
Published: (2021-02-01)

Optimization of Pharmacotherapy Within the Framework of a Patient-oriented Approach in the Treatment of Hypertension in Multimorbidity Patients (Clinical Case and Literature Review)
by: O. D. Ostroumova, et al.
Published: (2021-03-01)